HUTCHMED Presents Clinical Data at ESMO Asia Congress and ASH Annual Meeting

HUTCHMED will present clinical data at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting. The presentations will cover the anti-CD47 monoclonal antibody HMPL-A83, the fruquintinib and sintilimab combination for second-line renal cell carcinoma treatment, and the surufatinib and camrelizumab combination for first-line pancreatic cancer treatment. The data will provide insights into the efficacy and safety of these treatments in advanced solid tumors and metastatic pancreatic cancer.